

# Fighting male cancer

## **Orchid Cancer Appeal**

Annual report and  
financial statements  
2021-2022

# **Orchid Cancer Appeal**

## Annual report and financial statements 2021-2022

## Board of Trustees

Mr CS Osborne Chair  
Mr W Cohen Treasurer  
Mr D Badenoch  
Mr PG Bracher  
Mr S Harris  
Mr M Kibblewhite  
Professor RTD Oliver  
Mr P Norman  
Mr S Seymour  
(resigned 1 January 2022)  
Mr N Watkin  
(resigned 7 December 2021)  
Mr B Ayres  
(appointed 22 June 2022)

## Chief Executive

Mr A Orhan

## Independent Examiner

Moore Kingston Smith LLP  
6th Floor, 9 Appold Street,  
London EC2A 2AP

## Accountants

JS2 Limited  
1 Crown Square, Woking,  
Surrey GU21 6HR

## Legal advisors

Farrer & Co  
66 Lincoln's Inn Fields,  
London WC2A 3LH

## Bankers

HSBC Plc  
20 Electric Parade,  
George Lane,  
South Woodford,  
London E18 2LX

## Registered Office

60 Gray's Inn Road,  
London WC1X 8AQ

Tel 020 3745 7310  
[www.orchid-cancer.co.uk](http://www.orchid-cancer.co.uk)

Registered in England with the  
Charity Commission No.1080540

Company Limited by Guarantee  
Registered in England  
No. 3963360

# Inside this report:

<b>Welcome</b>	6
<b>CEO's letter</b>	7
<b>1. The year in review</b>	8
<b>2. Fundraising</b>	16
<b>3. Our impact</b>	20
Prostate cancer	22
Testicular cancer	24
Penile cancer	26
Research	28
<b>4. The year ahead</b>	30
<b>5. Governance</b>	36
Objects, operating context and activities	38
Structure, Governance and Management	38
<b>6. Financial review</b>	42
Formal statements	44
Independent Examiner's information	45
Independent Examiner's Report	46
Statement of financial activities	47
Balance sheet	48
Statement of cash flows	49
Notes to the financial statements	50

# Welcome from our Chair

**Orchid has again worked tirelessly throughout the year, to support those affected by prostate, testicular or penile cancer. As well as to help people understand the risk factors of male cancers and to prevent the worst prognoses in the future.**

To this end, we have continued to invest in world-class male cancer research to benefit both current and future generations of men. Orchid's roots are in male cancer research, our past studies have significantly advanced the understanding of male cancers. Building on this, the Trustees and I agreed further funding for the Robert Lane Tissue Bank. Led by Professor Dan Berney MB B Chir, MA, FRCPath, the work focusses on translating research into practical interventions for patients via novel tests and bespoke predictive treatments.

Led by our CEO Ali Orhan, in his capacity as Director. Orchid has made excellent progress on our three-year programme: 'Overcoming the Barriers to Engaging with Prostate Cancer', funded by the National Lottery Community Fund. Through this substantial piece of work, Orchid will be reaching men at high risk and in some of the most deprived areas of the country.

Work is ongoing to increase the number of peer support opportunities in collaboration with a variety of other organisations. This is as an effective and personal way to provide information and support to those affected by a male specific cancer. Orchid's collaborative working approach means that Orchid not only shares its expertise, but reaches more men and relevant healthcare professionals, with our information and advice. One highlight next year will be our Specialist Nurse Rob

Cornes, presenting a session at the European Association of Urology (EAU) conference in Milan in 2023, together with Orchid's patient advocates.

Securing funding in these tricky times has become more of a challenge, and we expect this to continue. However, I am delighted to report that Orchid increased its fundraising effort as per our strategy and gained a significant increase in income, which puts us on secure ground to continue our work.

Orchid's work is only possible because of the dedication of our staff, the commitment of our volunteers and the generosity of our supporters. The trustees and I are incredibly grateful to everyone who contributed towards our efforts in the last year, and offer a warm welcome to those who will support us in the year ahead.

Colin Osborne MBE

# CEO's letter

**It was a successful year of delivering against our objectives. As we emerged from COVID-19 restrictions, we were able to reach those at risk, especially people from marginalised communities, by delivering our Male Cancer Information Roadshows in the heart of local communities, reaching over 8,000 people with information and support.**

We were able to maintain increased operational hours for Orchid's confidential Male Cancer Helpline and therefore sent a greater number of referrals to the penile and testicular cancer telephone counselling service. The Overcoming the Barriers to Engaging with Prostate Cancer project is fully underway and almost 4,500 people received prostate cancer information from Orchid's trained Volunteer Community Champions. We are extremely grateful to the Task-Force members who help to drive this project. Orchid also identified the need to reach out to trans women who may be at risk of prostate cancer, and we thank the National Lottery Awards for All England for their grant to begin this work.

We worked in many collaborative partnerships this year such as with breast cancer charity CoppaFeel! to produce posters for schools to raise awareness of breast and testicular cancer. We also inputted into a series of four new videos about testicular health by the British Fertility Society.

As we look forward, Orchid will be aiming for excellence in its health information and the team will be reviewing our information assets to ensure that it is the most up to date

and that it achieves the PIF TICK quality mark for UK health information.

We want to ensure that information about the three male-specific cancers, our resources and Nurse-led support services reaches more people via the development of a new Orchid website and our social media platforms. We already use online and digital platforms to good effect to disseminate male cancer messages, promote educational films, encourage people to view and download information, inspire people to donate and also access further services and support, and we want to build further on this.

As we face an uncertain economic climate in the UK, Orchid will continue to keep a diversified fundraising strategy by including individuals as well as Corporate and Charitable Trust supporters.

I am extremely grateful to those who have made our successes possible – not only our dedicated staff, trustees, volunteers, and patient advocates, but also our donors, Corporate partners, new and existing loyal supporters, organisations with which we collaborate to help reach new audiences, and people who have shared their personal stories to help us raise awareness of prostate, testicular and penile cancer.

Ali Orhan, CEO

# 10



# The year in review

Increased helpline hours maintained

Roadshow programme reaches targeted communities

Penile cancer advocate performs at Edinburgh Fringe

New resources launched

Supporting research for practical treatments

There are more than 55,000 new cases of prostate, testicular and penile cancer each year in the UK. Sadly around 12,000 people will die from these diseases, but thankfully, many will also recover. In response, Orchid has worked throughout the year to support those affected, as well as to help people understand the risk factors, changes to look out for, and the need to get help as soon as possible if concerned. The charity has also continued to invest in world-class male cancer research to benefit both current and future generations of men.

**Orchid's Freephone confidential Male Cancer Helpline has remained at the heart of the charity's Nurse-led services, and the increased hours introduced in response to the COVID-19 pandemic continued.**

The number of calls taken by our Nurse was in line with the previous year, but an increased number of referrals to the penile and testicular cancer counselling service were made. The peer support sessions which Orchid help facilitate were delivered both virtually and in person, and Orchid Nurse Rob Cornes continued to support the St Bartholomew's Testicular Cancer Support Group.

Reaching those at risk was a priority, especially people from marginalised communities who may not engage with mainstream health messaging. Orchid was active delivering Male Cancer Information Roadshows in the heart of local communities in targeted locations from Aberdeen to Lancaster, and Derby to Hackney. Orchid met over 8,000 people via the Roadshow programme, with others learning about male cancer via the Health at Work programme and awareness talks. In addition, almost 4,500 people received prostate cancer information from the Orchid Volunteer Community Champion team via the Overcoming the Barriers

to Engaging with Prostate Cancer project. Orchid has also identified the need to reach out to trans women who may also be at risk of prostate cancer, and a grant was received from the National Lottery Awards for All England to begin this work.

In August 2022 Orchid supported comedian Mr Richard Stamp, a penile cancer survivor and advocate, who performed his one man show about his experience of penile cancer at the Edinburgh Fringe Festival for three weeks. This show is a hard-hitting journey through his diagnosis and treatment and won critical local acclaim. Orchid organised and supported a support meeting

following one of these shows for other survivors and health care professionals working in the field of penile cancer.

In recent years reaching people digitally has become increasingly effective and both Male Cancer Awareness Week and International Penile Cancer Awareness Day were driven by social media. Social media content over the year has also been used to share male cancer information as well as links to direct people to the Orchid website, and to the portfolio of paper based and online resources such as our PSHE Association accredited lesson plan and the Your Privates testicular cancer microsite.



A new poster series included one for each male cancer, one about all three, and one on how to access Orchid's support and information




A number of new resources were developed and launched in the year to support our awareness activities. These include a fold out 3 in 1 leaflet about all three male-specific cancers called “Prostate, Testicular and Penile Cancer. Get to know the facts and how to spot them,” as well as a series of five posters. The poster series has one about each male cancer, one

about all three, and one about the support Orchid can offer. Orchid was pleased to contribute to an initiative created by breast cancer charity CoppaFeel! to produce downloadable educational posters for schools to raise awareness of both breast and testicular cancer, as well as to a series of four new videos about testicular health by the British Fertility Society.

In the period Orchid Nurse Rob Cornes began a review of Orchid's information with view to attaining the PIF TICK which is the UK-wide Quality Mark for Health Information. Orchid also started work on the development of a new website to offer more accessible information about all three male cancers, collaborated with Ansar Projects and

CoppaFeel! on the development of testicular and breast cancer resources to support people with a learning disability to know their body, started making a film called *Take Three* which will tell the stories of people affected by each of the male cancers together with a booklet telling nine real life stories, and a film about advanced prostate cancer.

Orchid also worked in close collaboration with health and social care professionals, policy makers and other cancer charities to bring about positive change for men and their families. Examples include continuing to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the



UK, and with both Prostate Cancer Research and TACKLE Prostate Cancer on promoting the activities the different charities carry out.

Research is vital to understand why men develop prostate, testicular and penile cancers and to improve diagnosis and treatment. This is why Orchid continued to support world-class research by making a grant towards the Robert Lane Tissue Bank incorporating the Circulating Tumour Cells (CTCs) project. The work in the Tissue Bank is focused on the pathology and natural history of prostate, testicular and penile cancer, and on translating basic research into practical treatments for patients with novel tests and bespoke predictive treatments. Circulating Tumour Cells (CTCs) are held in the Tissue Bank for experimental research about cancer genetics and circulating biomarkers, including Circulating Tumour Cells.

Having previously reviewed training need, our small staff team undertook Diversity and Inclusion training, and two bespoke sessions on the use of our fundraising database.

**A fold out 3 in 1 leaflet about all three male-specific cancers was launched**

**We continued to work in collaboration with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer**



23,351



pieces of specialist information requested by individuals, organisations and healthcare professionals



4,821

people received prostate cancer information from Orchid Community Champions and other experienced volunteers




184,104

page views on the Orchid website


3,693


men, women and healthcare professionals had in-depth male cancer support or information directly from an Orchid Nurse / Male Cancer Information Manager

24,096



pieces of specialist information disseminated through outreach activities






5,400

sessions on *Your Privates* testicular cancer microsite

824,734

Organic reach of Orchid's social media platforms



8,195 people had the opportunity to learn about male cancer by attending an Orchid Roadshow



26

Number of peer reviewed papers to which Robert Lane Tissue Bank contributed



100

testicular and penile cancer counselling sessions delivered

# 2.



# Fundraising

Significant growth in funds raised

Support for cancer research

Payroll giving a growing source of unrestricted funds

Jonathan Freedland's Radio 4 Appeal for Orchid

# Fundraising

Working to save the lives of those diagnosed with prostate, testicular or penile cancer is only possible because of the generosity of our wonderful supporters, be they individuals, community groups, Trusts and Foundations or Companies.

Throughout a successful fundraising year, so many people gave donations because of having been touched in some way by male cancer and in memory of loved ones. The Orchid team cheered on supporters at large events such as the London Marathon and London Landmarks Half Marathon, as well as helped and encouraged the many individuals and groups who were busy fundraising across the UK through activities such as cake sales, the Twyford Beer Festival, running events, our new step challenge, and art events.

There were some significant grants during the year from Charitable Trusts and Companies restricted to developing innovative information resources, delivering Nurse-led services to support those affected, and reaching out to raise awareness in the heart of local communities. Considerable support was received to fund male cancer research, and a grant was received from the National Lottery Awards for All England to fund a project called "Trans women get prostate cancer too." Payroll giving continued to be a growing and valuable source of unrestricted income. Furthermore, two legacy payments made a remarkable contribution to income in the year.

A total of £841,808 was raised during the year which showed significant growth on £530,278 raised in the previous year. Each donation and grant given was a vital contribution, and Orchid would like to thank everyone who helped us in any way as income was regrown after the negative impact of COVID-19.

Incorporating learnings is important to Orchid. Throughout the year Orchid staff and Trustees continued to review our fundraising activities and sought to identify new opportunities to ensure we retain a diverse and cost-effective fundraising base to balance risk in the years ahead.

During the year we moved to the Fundraise Up platform to engage more supporters and improve the donor experience.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and

putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies.

Orchid operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board of Trustees.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received one complaint in relation to our fundraising activities which was resolved in line with our procedures. We remain committed to improving our practice, learning from supporter feedback.

## Radio 4 Appeal

Orchid was delighted to be selected as a beneficiary of the weekly BBC Radio 4 Appeal. Furthermore, we were thrilled that leading broadcaster and journalist, Jonathan Freedland, was able to present Orchid's Appeal which went out on Easter Sunday 2022.

In the Appeal, Jonathan spoke very movingly of his own family experience of prostate cancer, telling listeners that his grandfather and father had both been diagnosed with this cancer which now affects over 52,000 men each year. He also shared the story of Orchid supporter, Glenn, who was stunned to be diagnosed with testicular cancer at the age of 55. Like many, Glenn had believed that testicular cancer only affected younger people. Jonathan

spoke about Glenn's relief at finding the support of Orchid's Male Cancer Nurse Specialist after he called our confidential Helpline. Jonathan also explained how speaking to an Orchid Nurse gave Glenn a better understanding of the potential impact of the cancer on his physical and mental health, which made him less fearful. The Appeal focused

on Orchid's Helpline which is run by Specialist Nurses. It also highlighted the continued need for donations to meet the demand by those seeking support and information about their prostate, testicular or penile cancer concerns. BBC Radio 4 listeners were generous in their support, and together they raised £16,109 towards Orchid's work.



**Jonathan Freedland, journalist, author and broadcaster, who presented Orchid's Radio 4 Appeal on Easter Sunday 2022**

# 3.

# Our impact

Prostate cancer

Testicular cancer

Penile cancer

Research

# Our impact

## Prostate cancer

**Over 52,000 people are diagnosed with prostate cancer in the UK annually, that's more than 140 people every day. Sadly, there are 11,855 deaths from prostate cancer each year with 10-year survival at around 78%. According to CRUK, one in six UK males will be diagnosed with prostate cancer in their lifetime.**

With more and more men being diagnosed with prostate cancer it is becoming more essential to correctly identify those who may be at risk of disease progression and those with mild or inactive disease.

One of the interesting directions that this may take are so called liquid biopsies - the sampling of circulating cancer cells within the blood. Orchid has helped fund research into circulating tumour cells or CTCs and this method along with a more frequent use of MRI scans to identify potential areas of prostate cancer may improve medical assessment dramatically and reduce the side effects men may experience from cancer treatment.

In addition, those men with minimal risk of disease progression are likely to be managed by active surveillance. This is an option that is likely to increase dramatically over the next few years and one which Orchid has already created information about.

Some men who are put on active surveillance may take 6-months or more to adjust to the fact that their cancer does not require immediate treatment and Orchid has responded to the need for information and support to help them.

One of the greatest challenges around prostate cancer remains the unequal risk of this cancer among Black African and Black Caribbean men who are twice as likely to develop prostate cancer than Caucasian men. Creating awareness in this community and helping support Black men diagnosed with prostate cancer is crucial. Although there are over 95 prostate cancer support groups in the UK, the Black community remains underrepresented.

A need also exists to reach trans women and non-binary people assigned male at birth with prostate cancer messaging, as they too can be diagnosed with this cancer.



## Overcoming the Barriers to Engaging with Prostate Cancer

May 2021 saw the start of a three-year project funded by The National Lottery Community Fund entitled *Overcoming the Barriers to Engaging with Prostate Cancer*. This work is led by Ali Orhan in his capacity as Project Director, alongside his role as Orchid CEO.

The project is running in Birmingham, Bradford, Bristol, Dudley, Leeds, Liverpool, Manchester, Newcastle, Nottingham and Wolverhampton, and was gaining real momentum as we entered the reporting year.

Throughout the 12-month period a growing number of Volunteer Community Champions were recruited and trained. Our team – which numbered 82 by the year

end – comprises community members, healthcare professionals and prisoners, and they cascade prostate cancer messages using the tool kit and leaflets developed by the Orchid project team, as they target those at risk within their own communities.

In the year, our Volunteer Community Champions reached 4,488 people with prostate cancer information. They had 1,114 in-depth conversations about this cancer, with evaluation showing the difference this made to the beneficiaries. 4,642 prostate cancer leaflets were disseminated, plus a further 3,503 leaflets signposting people to local services. The largest group reached were men, but women also were keen to gain knowledge for the men in their lives.

Our Champions used their own local knowledge to inform their choice of awareness raising activities. Some examples included: talking to and reaching people via information stands in libraries; health and other community events including festivals; on buses and trains; in markets, taxis,

and GP surgeries; by virtual talks; attending men's groups; the Amazon Distribution Centre in Newcastle; the Armed Forces Day in Wolverhampton; and via food banks.

Trained Community Champions also cascade prostate cancer in three prisons – HMP Dovegate, HMP Stafford and HMP Oakwood. Some of the training had been delayed because of COVID-19, but despite this, these Champions reached 337 men and had 109 in-depth conversations.

In Orchid's financial year 2022-2023, Orchid will be returning to the ten locations to meet with the teams of Volunteer Champions to celebrate their successes and to discuss the challenges, sharing regional learnings to all the Volunteer Community Champions. The Orchid team will be discussing the case studies reported by the Champions, as well as looking forward to determine how prostate cancer awareness can continue after the project ends in May 2024, and to ensure there is a positive project legacy in each location.



Our Volunteer Community Champions reached 4,488 people with prostate cancer information. The largest group reached were men, but women also were keen to gain knowledge for the men in their lives.

# Our impact

## Testicular cancer

**Testicular cancer is rare with around 2,300–2,400 diagnoses each year in the UK. Around 60 men will die each year from testicular cancer although it remains potentially the most treatable and curable type of cancer with over 90% of men surviving 10 years.**

Testicular cancer tends to affect a younger age group than most other cancers, with nearly 50% of men diagnosed under the age of 35, and 80% of those diagnosed between the ages of 15-45. This means that testicular cancer will often affect men at a stage of their life where they may be starting a family or career, or just consolidating their place in life. Treatment occurs quickly with men often being diagnosed and treated within a few weeks.

As well as surgery to remove the affected testicle, treatment may also involve chemotherapy. In addition to temporary side effects, chemotherapy can increase the risk of cardiovascular disease in later life.

Challenges around testicular cancer involve supporting men in adjustment

to life following treatment. Many men will only realise the full implication of their cancer journey when treatment ends and may not be able to access either peer support or psychological support. Orchid has consistently supported the biggest testicular cancer support group in the UK, which is co-ordinated by the specialist nurse team at St Bartholomew's in London, both physically and virtually.

In addition, the creation of Orchid's telephone counselling service allows men to access psychological support without the necessity of waiting for extended periods of time.

Orchid also continues to work with the Testicular Cancer Network to improve the resources available to those affected by testicular cancer throughout the UK.

**Testicular cancer is the most common cancer in young men – many older men are not aware they remain at risk and may ignore potential symptoms.**





## Male Cancer Awareness Week 2022

**Male Cancer Awareness Week unites individuals and organisations from around the UK to help raise awareness of prostate, testicular and penile cancer.**

Every year the week highlights the importance of being aware of the risk factors and early signs or symptoms of these three cancers, and the importance of getting checked out by

your GP if concerned. The theme of the Awareness Week in 2022 was 'Older Men Get Testicular Cancer Too!'

Due to the period of National Mourning following the death of Her Majesty Queen Elizabeth II, Orchid delayed its Male Cancer Awareness Week which was planned for 12th to 18th September, until 26th September to 2nd October.

The messaging was delivered mainly digitally with a series of infographics delivered each day across Orchid's social media, and that of partners and supporters, as well as by targeted advertising. Testicular cancer is the most common cancer in young men and many older men are not aware they remain at risk and may ignore potential symptoms.

The infographics and accompanying text covered the risk factors, the potential signs and symptoms, and how men can check their testicles to understand what is normal and what may be a potential sign of this cancer. Our posts also highlighted the information available on the Orchid website, and that the Orchid Helpline run by experienced Male Cancer Nurse Specialists is there for anyone with a concern.

Through Orchid's own social media channels, we had an organic reach of over 6,500 with these important messages.

Paid social media advertising and radio coverage took the total number of opportunities to learn about testicular cancer to over 422,500.



# Our impact

## Penile cancer

**Penile cancer is exceptionally rare in the UK with around 700 men being diagnosed each year. Around 170 men will lose their lives to the disease although 68% of men will survive 10 years following their diagnosis.**



Most men will never meet another man affected by penile cancer, so Orchid has focused on developing a telephone counselling service to support men and has created events to offer peer support.

Out of the three male-specific cancers, penile cancer has the potential to cause the most physically and psychologically damaging side effects, as all curative treatment will involve some form of surgery to the penis itself. This can be minimally invasive but may also involve partial or total amputation of the penis resulting in a radical change in body image and sexual function.

Due to its intimate nature around 15-50% of men will delay seeking treatment. Delaying penile cancer treatment can lead to disease progression of the primary tumour such that organ-sparing surgery may no longer be feasible. In addition, 20-25% of penile cancer may be misdiagnosed with men being referred to dermatologists and sexual health clinics.

Treatment is performed at specialist regional treatment centres in the UK with dedicated teams performing penile sparing surgery.

The main challenges for Orchid around penile cancer are creating awareness of the disease – many people do not realise penile cancer exists, and the isolation which men may feel following treatment. Most men will never meet another man affected by penile cancer due to its

rarity therefore missing out on invaluable peer support. In addition, there is an unmet need to support these men psychologically. When men realise that they may need psychological help such as counselling there is often a severe delay in referral.

Orchid has therefore focused on the development of a telephone counselling service to support men and wherever possible has created events to offer peer support, as well as supporting and encouraging allied healthcare professionals in the creation of regional support groups.

With 83 cases a year, there is a higher incidence of penile cancer in Scotland in comparison to the rest of the UK, and those affected by penile cancer in Scotland are also being diagnosed at a younger age. A penile cancer diagnosis can be psychologically devastating, and treatment can be challenging especially if the diagnosis has been made at a late stage.

Orchid has significant experience of educating people about the signs and symptoms of penile cancer, as well as understanding the complex

issues involved in supporting penile cancer patients.

Whilst we do not as yet know why Scotland has a higher incidence proportionally than the rest of the UK, we do know that many people have not heard of penile cancer, let alone know what potential symptoms might be. This is why Orchid identified the need to deliver a project to put penile cancer on the agenda in Scotland, and whilst delivery of this specific piece of work is complete, many of the elements have now been brought into Orchid's core services.

## Orchid's collaborative work

**Orchid is pleased to continue its collaborative work with the European Reference Networks (eUROGEN) to improve the patient pathway for men with penile cancer across Europe. In addition, Rob Cornes is now a member of the EAU Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid.**

In August 2022 Orchid Nurse Rob Cornes and two men with penile cancer, who have been supported and empowered by Orchid to act as Patient Representatives or ePAGs, gave a lecture at the European Association of Urology (EAU) Conference in

Amsterdam. This session highlighted the unmet needs of penile cancer patients and was based on a peer reviewed article written by Rob Cornes and published in the prestigious journal Seminars on Oncology Nursing.

Orchid is working collaboratively with eUrogen and is in the process of creating a suite of resources about penile cancer. These resources will consist of two humorous awareness videos, one aimed at the general public to raise awareness of penile cancer and the other to encourage GPs and primary care workers to refer men with any suspicious penile lesion urgently to a urologist. A further animated video is being scripted by Rob Cornes and created by the EAU

about penile cancer. With further funding a future video will be created dealing with management strategies for men living with the side effects of the disease. A patient experience booklet will also be created to provide guidance for health care professionals caring for penile cancer patients.

During the year Orchid also joined the Human Papilloma Virus Coalition, a consortium of numerous charities working in the field of HPV education, awareness and prevention. Regular meetings and collaboration will continue over the next few years. Around 50% of men diagnosed with penile cancer will have evidence of certain types of HPV infection which increase the risk of the disease.

# Our impact

## Research

**Orchid was pleased to continue its support for the work of The Robert Lane Tissue Bank incorporating the Circulating Tumour Cells (CTC) project during the year.**

### Ongoing work includes:

- TAPG (the study with the Trans-Atlantic Cohort). Further papers are ongoing, with one in 'major revision at present' and another in preparation.
- Testis. Further collaborative work with Denmark continues, with 2/3 papers in preparation for 2023.
- A new collaboration looking closely at Sex cord stromal tumours of the testis has just been initiated. This International collaboration has support for 2023 from two international pathology organisations (The International Society of Urological Pathology (ISUP) and The Genitourinary Pathology Society (GUPS) for these challenging to treat tumours.
- STAMPEDE. Work is ongoing for publication in 2023/24. (STAMPEDE is a clinical trial looking at the best way of treating men with newly diagnosed advanced prostate cancer.)
- Review a manuscript on using CTCs for early detection of aggressive cancer: a synopsis has been submitted to Nature Review Clinical Oncology (Impact factor 62) and approved by the editors for full manuscript submit (to be submitted in January 2023).
- CTC clusters as prostate cancer prognostic biomarkers: a manuscript to be completed in 2023.

During the period, Orchid funded work has contributed to the following books:

- Chapter: Testicular Neoplasia. Sternberg's Diagnostic Surgical Pathology (2 Volume Set) 2022.
- Urinary and Male Genital Tumours. WHO Classification of Tumours, 5th Edition, Volume 8 WHO Classification of Tumours Editorial Board

A full list of papers for the period is available on request.

The Robert Lane Tissue Bank is headed by Professor Dan Berney, MB BChir, MA, FRCPath who is an Honorary Professor of Genito-urinary Pathology; Consultant Pathologist. Professor Berney has lectured throughout the world and is an internationally recognised pathology expert in the three male genito-urinary cancers.

Professor Yong-Jie Lu MBBS, MD, PhD, and Professor of Molecular Oncology, who leads the Circulating Tumour Cells Project, has worked on cancer genetics research for 30 years. Professor Lu has developed a number of novel cancer genetic analysis techniques and was first to identify the genetic difference in prostate cancer between the Chinese and Western population.

The Robert Lane Tissue Bank is an internationally significant resource for past and future research into all three male-specific cancers. Rather than collecting all tumours, it is a 'bespoke' bank often with long term clinical follow up and connected to clinical trial data. It holds tumours from nine separate clinical trials; over 600 penile cancer specimens, over 3,000 testicular cancer specimens, and over 6,000 prostate cancer specimens; and more than 1,200 blood samples collected and separated into Circulating Tumour Cells (CTCs), plasma, red blood cells,

white blood cells and platelets for separate storage and future research.

In 2022 The Robert Lane Tissue Bank contributed to 26 peer reviewed papers. This record-breaking number included 10 papers where, although the Tissue Bank had contributed data as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium, Professors Berney and Lu were not a named author, nor any other consortium member. This was changed as an Author correction to these papers in December 2022. The papers were published in 2020-2022 and have not previously been mentioned in Orchid's work. Many are now highly cited. This emphasises how the tissue collection has made a huge



contribution to international research. Abstracted work was presented at the United States and Canadian Academy of Pathology USCAP 2022 meeting in March on prostate cancer (accepted platform presentation) in Los Angeles, and at the European Congress of Pathology in September in Basel.

The Circulating Tumour Cell (CTC) and biomarker studies have shown that CTCs and gene expression analysis can predict prostate cancer patient response to the chemotherapy drug docetaxel with a manuscript accepted recently by Frontiers of Oncology. Blood samples (over 200) have been collected from prostate cancer patients, patients with suspected prostate cancer and

Over 200 blood samples have been collected from prostate cancer patients and healthy volunteers, and stored for future research

healthy volunteers, with CTCs isolated and other blood components separated and stored in -80°C freezer (over 1000 items) for future research.

Further CTC analysis confirmed that CTC positivity predicts prostate cancer aggressiveness and biopsy outcome. It also showed that CTC clusters (two or more CTC stick together in the blood) are associated with aggressive prostate cancer and a manuscript is in preparation.

CTC work as prostate cancer diagnostic and therapeutic biomarkers has been presented as invited talks at the 2021 UK National Cancer Research Institute Annual Meeting (November 2021); The BioTech Pharma Summit 2021 – Antibody Engineering Biomarkers Biobanking and Liquid Biopsy (Porto, November 2021); Prostate Cancer UK Spotlight on... webinar series – Spotlight on blood biomarkers (June 2022); Public Policy Exchange webinar series – Improving Cancer Screening in the UK (August 2022); 4th Annual Biomarker and Companion Diagnostics Conference (London, October 2022); 8th Taihu Chinese Urological Symposium and 8th Huishan Precision Medicine Summit (Wuxi, China, November 2022); and European Liquid Biopsy Society Circulating Tumour Cell technology workshop (December 2022).

# 4.

# The year ahead

New film to start conversations about male cancer

Booklet to highlight nine real life encounters with cancer

Support for people with learning disabilities to know their body

New website to be launched

More Volunteer Community Champions to be recruited

# The year ahead

**The reporting year ended with the successful delivery of Orchid's fourteenth Male Cancer Awareness Week which, whilst highlighting all three male-specific cancers, had a particular focus on "Older men get testicular cancer too." Knowing that male cancer is easier to treat and cure if it is discovered early, raising awareness of male cancer risk factors, signs and symptoms remained a priority as we entered the new financial year.**

Plans were in place to launch new educational resources in the early part of the year including two new films. *Take Three* will tell the story of three people affected by male cancers to start important conversations, and a film will help those diagnosed with advanced prostate cancer better understand their condition. Work will also start on another film which will be used to deliver targeted prostate cancer messages as well as providing information and support to those diagnosed.

Other resources to be launched early in the year include a booklet which will describe nine real life encounters with prostate, testicular and penile cancer. Again, its aim is to encourage

Plans are in place to launch new resources in the early part of the year which will start important conversations about male cancers





people to talk about these cancers and to learn what to look out for. Another addition to our portfolio will be a series of accessible resources developed with Ansar Projects and CoppaFeel! to support people with a learning disability to know their body. The resources will be the first of their kind and will include accessible testicular and breast cancer information packs, self-checking cards, testicular and breast cancer symptom guides, self-checking social stories and information on what to expect if you notice a change.

December will see the launch of the new Orchid website, with more accessible information and resources which will be available to order and download. The review of Orchid's information is ongoing with view to attaining the PIF TICK, the UK-wide Quality Mark for Health Information.

Community outreach will continue with Orchid's successful Male Cancer Information Roadshows run in targeted identified locations, delivered as funding is received. Alongside Roadshows, talks and presentations, Orchid plan to grow its Health at Work

programme. Plans are in place to recruit and train further Volunteer Community Champions through the National Lottery Community Fund project, Overcoming the Barriers to Engaging with Prostate Cancer. The project team are in regular contact with those who are already using their knowledge of their local communities to cascade prostate cancer information to support their outreach, and the learnings coming out of regionally based conferences planned for Spring 2023 will be shared widely.

Orchid's Male Cancer Awareness Week will take place between 11-17 September 2023, leading on to the third International Penile Cancer Awareness Day.

Supporting those affected by male cancer is also a high priority for the coming year. The Freephone National Male Cancer Helpline will continue to operate its increased hours for anyone worried about prostate, testicular or penile cancer. We also remain committed to delivering and co-facilitating peer support opportunities. In collaboration with the Maggie's Centre at the Christie Hospital in

Manchester, Orchid will help run a penile cancer support group every two months. A similar group had been set up prior to the pandemic as a direct result of an Orchid initiative. Now the group will reform in 2023 and working with the Christie penile cancer team Orchid will seek to further its contacts within this community. We will continue to offer a telephone counselling service to those affected by penile or testicular cancer.

Social media will be used to relay male cancer messages, promote our educational films and to drive followers to the Orchid website or to view, order or download resources. Posts will be developed incorporating the learnings of the last year when we found that the audience was more reactive to awareness and personal stories.

Orchid Nurse Rob Cornes works with healthcare professionals both in the UK and beyond to improve the patient journey for those with penile cancer. Orchid resources and services will be promoted throughout the year to healthcare professionals working in the relevant fields throughout the UK.

Through his work with the European Reference Networks (eUROGEN) Rob Cornes and the patient advocates Orchid identified will present a further session on communicating accurate medical information to patients for rare cancers at the European Association of Urology (EAU) conference in Milan in 2023. In addition, Rob Cornes, who is now a member of the EAU Patient Advocacy Group representing both testicular and penile cancer on behalf of Orchid, will provide two further talks at the upcoming EAU 2023 conference and take part in two panel discussions.

Orchid's roots are in male-cancer research. In recent years Orchid funded research has significantly advanced understanding of male cancers, and we will continue to invest in world-class male cancer research to benefit the well-being of current and future generations of men. Going into the year, Trustees agreed further funding for the Robert Lane Tissue Bank. The Tissue Bank is led by Professor Dan Berney MB B Chir, MA, FRCPath and is an internationally important resource for research into penile, testicular, and prostate cancer. Professor Berney is focused on translating basic research

into practical treatments for patients with novel tests and bespoke predictive treatments.


Donations have been received for the Orchid Research Innovation Fund. Trustees plan to award a significant grant from funds secured in the coming year.

Securing adequate funding at the best possible return on investment is essential to deliver our ambitious plans for the year ahead. After seeing income increase in 2021-2022, our fundraising strategy for 2022-2023 focusses on growing revenue further across all income streams.

The new year started with a wonderful team of runners fundraising for Orchid in the London Marathon, and 2023 will see both existing and new supporters taking part in a number of different running events, as well as in Orchid's unique Willy Waddles in London and Edinburgh. We are grateful to our supporters who are planning events such as a charity ball, a cycle ride and beard competitions, in addition to the annual and extremely successful Twyford Beer Festival.

We will continue to submit application to Charitable Trusts and

Social media will be used to relay male cancer messages and to drive followers to the Orchid website



Foundations on a rolling basis, and carry out research to identify new potential supporters. We will work with our corporate supporters to meet their needs as well as Orchid's and will explore corporate opportunities in the areas in which the Overcoming the Barriers to Engaging with Prostate Cancer project is running. We will also continue to explore other new income generating opportunities.

Looking after our supporters is paramount. We will continue to offer the best possible support to our corporate partners, the Charitable Trusts and Foundations who give to us, and all the individuals and community groups who support us with donations and fundraise on our behalf.

Orchid recognises its responsibility to reduce its carbon and environmental footprint and will continue to monitor its activities in relation to our Environmental Policy.

Orchid's work is only possible because of the generosity of our supporters. We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead.

We will explore corporate opportunities in the areas in which our *Overcoming the Barriers to Engaging with Prostate Cancer* project is running



# 5.

# Governance

**Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK.**

## **Objects, operating context and activities**

### **Objects**

Over 55,000 people in the UK are diagnosed with prostate, testicular or penile cancer every year and sadly this number is increasing. Orchid's aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

### **Operating context and activities**

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers,

how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

## **Structure, governance and management**

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chair's aim to maintain a balanced composition. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meet four times during the year and, at the Annual General Meeting, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from office in rotation, in order of longevity of appointment and are eligible to be reappointed.

Throughout the COVID-19 pandemic Trustees met virtually and continued to do so in 2021-2022.

## Trustee training and induction

On appointment, Trustees are offered a comprehensive induction programme which includes a meeting with the lead programme researchers and visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

## Delegation and decision-making

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance Committee is responsible for the financial oversight of the Charity including budgeting, financial planning and monitoring as well as financial reporting and the creation and monitoring of internal controls and accounting policies. It presents a

report to the Board at each of its meetings. As at 30 September 2022, it comprised the Honorary Treasurer, Mr W Cohen, Mr C Osborne, Mr M Kibblewhite, Mr S Seymour and Mr S Harris.

- To improve efficiency, Sub-Committees have been reviewed, and the Fundraising Sub-Committee meets as required.
- At the operational level, the Board delegates the day-to-day running of the Charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction. The Board is kept apprised of personnel, awareness, research programme and budgetary issues.

## Public benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit including (PB2 Public Benefit: Running a Charity).

## Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept

fully informed of the organisation's strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

## Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the verification of outcomes, a Scientific Advisory

Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding.

## Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identifies risks under the following headings:

### **Governance and compliance**

#### **Operational**

#### **Financial**

#### **Research**

#### **Environmental/external**

#### **Quality assurance**

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed regularly and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified. These are as follows:

## **Governance and compliance**

### **Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to**

#### **Mitigation**

- An ongoing review of the composition of the Board of Trustees to ensure that all key functions, including medical, legal and financial, are covered by suitably qualified professionals
- Training and support for Board of Trustees and Finance Committee
- Dedicated specialist resource applied in key areas e.g. health and safety, HR and legal
- Ensuring that key management personnel and advisers are of a calibre to ensure that the Charity is aware of and compliant with regulatory and similar requirements



## Operational

### Attracting, developing and retaining talented staff in a competitive employment market

#### Mitigation

- Annual salary review to include benchmarking of compensation and benefits
- Staff development, training and succession planning programmes
- Communication programme to ensure staff are involved in the development of and progress towards Orchid's strategy and annual workplan

## Financial

### Economic pressures, impact of COVID-19, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

#### Mitigation

- Annual budgeting and ongoing management, reporting and monitoring of financial performance
- Diversification of income streams
- Ongoing consideration of market and consumer trends and regulations including GDPR

## Research

### Orchid's Research Programme fails to deliver results

#### Mitigation

- Scrutiny and approval of research funding applications by an expert Scientific Advisory Board
- Annual review of progress

## Environmental / external

### Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid's work

#### Mitigation

- Key personnel monitor public policy and the regulatory environment on an ongoing basis to ensure potential risks can be proactively managed
- Chief Executive and Nurse Specialists attend key events and forums to help shape agenda
- Chief Executive and the Board of Trustees routinely scrutinise alignment with, and progress of, Orchid's strategy

## Quality assurance

### Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

#### Mitigation

- Services developed, delivered and evaluated in line with agreed protocol and standards
- Nurse Specialists are members of the Royal College of Nursing (RCN) and the British Association of Urological Nurses (BAUN), and registered with the Nursing and Midwifery Council (NMC)
- All information materials and content regularly reviewed and updated
- High-quality training for staff

# 6.

# Financial review

## Results for the year

Income for the year ended 30 September 2022 totalled £841,808 (2021: £530,278). After total expenditure of £740,252 (2021: £673,004), the year's activities show a net surplus of £101,556 (2021: deficit of £142,726). Total reserves at the end of the year amounted to £541,836 (2021: £440,280).

## Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity's core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

The available free reserves net of tangible fixed assets are £162,113 (2021: £154,187). It is the Charity's policy to maintain free reserves of approximately 3-4 months of operating costs. At current levels of expenditure this equates to £160,000-£212,000.

## Formal statements Statement of Trustees' responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

## Independent Examiner's information

So far as each of the directors at the time the Trustees' report is approved is aware:

- a) there is no relevant information of which the examiner is unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees



C S Osborne  
Chairman of Trustees  
20/03/2023

## Independent Examiner's Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2022.

### Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

### Independent examiner's statement

Since the Company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

*Moore Kingston Smith LLP.*

James Saunders FCCA DChA

Date: **30 March 2023**

For and on behalf of  
Moore Kingston Smith LLP  
Chartered Accountants  
6th Floor, 9 Appold Street,  
London  
EC2A 2AP

## Statement of financial activities

(incorporating an income and expenditure account)

For the year ended 30 September 2022

	Note	Unrestricted Total £	Restricted Total £	Year ended 30 September 2022 £	Year ended 30 September 2021 £
Income from:					
Donations and Legacies	2	440,779	233,921	<b>674,700</b>	440,580
Charitable Activities	4	-	166,673	<b>166,673</b>	89,497
Trading Activities		309	-	<b>309</b>	177
Investment income		126	-	<b>126</b>	24
Total income		<u>441,214</u>	<u>400,594</u>	<b><u>841,808</u></b>	<u>530,278</u>
Expenditure on:					
Raising funds					
Fundraising (donations and grants)	5	185,431	-	<b>185,431</b>	185,083
Charitable Activities					
Education and Awareness	5	109,874	266,968	<b>376,842</b>	307,383
Research	5	127,859	50,120	<b>177,979</b>	180,538
Total expenditure		<u>423,164</u>	<u>317,088</u>	<b><u>740,252</u></b>	<u>673,004</u>
Net income / (expenditure) and net movement in funds	5,6	18,050	83,506	<b>101,556</b>	(142,726)
Reconciliation of funds					
Total funds brought forward		<u>278,966</u>	<u>161,314</u>	<b><u>440,280</u></b>	<u>583,006</u>
Total funds carried forward		<u>297,016</u>	<u>244,820</u>	<b><u>541,836</u></b>	<u>440,280</u>

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 13 to the financial statements.

## Balance sheet

As at 30 September 2022

	Note	£	30 September 2022 £	£	30 September 2021 £
<b>Fixed Assets</b>					
Tangible Assets	10		<b>3,891</b>		2,971
Intangible fixed assets	11		<b>9,204</b>		-
<b>Current Assets</b>					
Cash at bank and in hand		<b>590,444</b>		508,854	
Debtors	12	<b>108,806</b>		77,325	
		<b>699,250</b>		586,179	
<b>CREDITORS</b>					
Amounts due within one year	13	<b>(170,509)</b>		(148,870)	
<b>Net Current Assets</b>					
			<b>528,741</b>		437,309
<b>Total Assets less Current Liabilities</b>					
	14		<b>541,836</b>		440,280
<b>NET ASSETS</b>					
			<b>541,836</b>		440,280
<b>Represented by:</b>					
General Unrestricted Funds		<b>175,208</b>		157,158	
Designated Funds		<b>121,808</b>		121,808	
			<b>297,016</b>		278,966
Restricted funds			<b>244,820</b>		161,314
			<b>541,836</b>		440,280

The company is limited by guarantee.

For the year ending 30 September 2022 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 20th March 2023 and signed on its behalf by:



Mr C S Osborne  
Company number 3963360



## Statement of cash flows

For the year ended 30 September 2022

	2022		2021	
	£	£	£	£
<b>Cash flows from operating activities:</b>				
Net income/(expenditure) for the year	101,556		(142,726)	
Adjustments for:				
Depreciation charges	1,944		1,486	
Interest	(126)		(24)	
(Increase)/Decrease in debtors	(31,481)		59,261	
Increase/(Decrease) in creditors	21,639		(132,517)	
	<hr/>		<hr/>	
<b>Net cash provided by operating activities</b>		<b>93,532</b>		<b>(214,520)</b>
<b>Cash flows from investing activities:</b>				
Interest	126		24	
Purchase of fixed asset	(12,068)		(4,091)	
	<hr/>		<hr/>	
<b>Net cash used in investing activities</b>		<b>(11,942)</b>		<b>(4,067)</b>
Change in cash and cash equivalents in the year		<b>81,590</b>		<b>(218,587)</b>
Cash and cash equivalents at the beginning of the year		<b>508,854</b>		<b>727,441</b>
		<hr/>		<hr/>
Cash and cash equivalents at the end of the year		<b>590,444</b>		<b>508,854</b>
		<hr/>		<hr/>
<b>Analysis of cash and cash equivalents</b>				
Cash at bank and in hand		<b>590,444</b>		<b>508,854</b>
		<hr/>		<hr/>
		<b>590,444</b>		<b>508,854</b>

# Notes to the financial statements

## 1. Accounting policies

For the year ended 30 September 2022

### Basis of Preparation

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Charities Act 2011.

### Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements and have considered the external economic environment on the charity's operations. In particular, the trustees have considered the charity's forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future.

Income for 2021-2022 showed considerable growth post the COVID-19 pandemic, and together with careful financial management the charity had stabilised. The accounts for the year show a surplus after a significant deficit in the previous year, leaving historic cash funds in place.

The project funded by the National Lottery Community Fund; Overcoming the Barrier to Engaging with Prostate Cancer will continue to run until May 2024, and there is a strong events and community fundraising pipeline after the disruption of the pandemic. The potential to grow income from Corporate Partnerships and Charitable Trusts and Foundations is recognised, and plans are in place to recruit more regular givers. Fundraising plans allow for income from different funding streams to spread risk. The National Lottery funded project along with continued support from loyal donors and supporters will enable Orchid to continue to as a going concern.

The trustees confirm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity, therefore, continues to adopt the going concern basis in preparing its financial statements.

### Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

### Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

### Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a

purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment - 33 1/3% on written down value

### Intangible fixed assets and Amortisation

Intangible fixed assets are included in the balance sheet at original cost less accumulated amortisation.

Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the number of years of expected use. Assets are amortised at the following rate:

Website - 20% on straight line value

### Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal.

The purpose and use of the Charity's restricted funds is set out in the notes to the financial statements.

### Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

## Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity's objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity's objects.

Governance costs are those incurred in connection with the management of the Charity's assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure.

## Financial Instruments

The charitable company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

## Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

## Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

## Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

## Pension Scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year.

The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

## Employee Benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee's services are received.

## Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

## 2. Donations

			Year ended	Year ended
	Restricted	Unrestricted	30 September 2022	30 September 2021
	£	£	Total	Total
			£	£
<b>Current year</b>				
Individuals	68,800	118,087	<b>186,887</b>	143,844
Legacies	-	100,000	<b>100,000</b>	-
Corporates	-	36,814	<b>36,814</b>	35,771
Trusts and Foundations	165,121	44,600	<b>209,721</b>	114,300
Fundraising Events	-	141,278	<b>141,278</b>	146,665
Total	233,921	440,779	<b>674,700</b>	440,580
<b>Prior year</b>				
			Year ended	
			30 September	
			2021	
	Restricted	Unrestricted	Total	
	£	£	£	
Individuals	92,800	51,044	<b>143,844</b>	
Corporates	-	35,771	<b>35,771</b>	
Trusts and Foundations	97,250	17,050	<b>114,300</b>	
Fundraising Events	-	146,665	<b>146,665</b>	
Total	190,050	250,530	<b>440,580</b>	

### 3. Fundraising events

Current year			Year ended	Year ended
	Restricted	Unrestricted	30 September 2022	30 September 2021
	£	£	Total	Total
			£	£
Cycling events	-	658	<b>658</b>	11,257
Running events	-	68,646	<b>68,646</b>	56,100
Third party organised events	-	62,806	<b>62,806</b>	76,943
Other	-	9,168	<b>9,168</b>	2,365
Total	-	141,278	<b>141,278</b>	146,665

Prior year			Year ended	
	Restricted	Unrestricted	30 September 2021	
	£	£	Total	
			£	
Cycling events	-	11,257	<b>11,257</b>	
Running events	-	56,100	<b>56,100</b>	
Third party organised events	-	76,943	<b>76,943</b>	
Other	-	2,365	<b>2,365</b>	
Total	-	146,665	<b>146,665</b>	

### 4. Charitable activities

Current year			Year ended	Year ended
	Restricted	Unrestricted	30 September 2022	30 September 2021
	£	£	Total	Total
			£	£
The National Lottery Community Fund RC England-wide	166,673	-	<b>166,673</b>	89,497
Total	166,673	-	<b>166,673</b>	89,497

Prior year			Year ended	
	Restricted	Unrestricted	30 September 2021	
	£	£	Total	
			£	
The National Lottery Community Fund RC England-wide	89,497	-	<b>89,497</b>	
Total	89,497	-	<b>89,497</b>	

## 5. Total expenditure

Current year	Cost of	Education and	Research	Year ended	Year ended
	raising funds	Awareness		30 September 2022	30 September 2021
	£	£	£	Total	Total
				£	£
Grants	-	-	149,222	<b>149,222</b>	154,896
Staff costs	74,399	147,294	18,366	<b>240,059</b>	239,012
Fundraising expenses	68,941	-	-	<b>68,941</b>	51,935
Information materials	-	98,605	-	<b>98,605</b>	66,371
Direct costs	-	38,393	-	<b>38,393</b>	30,322
	<u>143,340</u>	<u>284,292</u>	<u>167,588</u>	<u><b>595,220</b></u>	<u>542,536</u>
<i>Support costs</i>					
Depreciation	558	1,248	138	<b>1,944</b>	1,486
Other	33,797	75,514	8,343	<b>117,654</b>	98,477
Governance - staff costs	5,869	11,618	1,449	<b>18,936</b>	24,628
Governance - examiners fees	1,867	4,170	461	<b>6,498</b>	5,877
	<u>42,091</u>	<u>92,550</u>	<u>10,391</u>	<u><b>145,032</b></u>	<u>130,468</u>
<b>Total expenditure</b>	<u>185,431</u>	<u>376,842</u>	<u>177,979</u>	<u><b>740,252</b></u>	<u>673,004</u>
<b>Prior year</b>	<u>185,083</u>	<u>307,383</u>	<u>180,538</u>	<u><b>673,004</b></u>	

## 6. Grants awarded

	Year ended	Year ended
	30 September 2022	30 September 2021
	Total	Total
	£	£
Grant commitments brought forward	<b>87,576</b>	205,415
Institutional grants for medical research awarded during year/period		
Orchid Study and Travel Awards (2022: 2 individuals 2021: 0 individual)	<b>2,000</b>	-
Barts and London School of medicine	<b>144,652</b>	138,896
Payments made during period/year	<b>(107,611)</b>	(256,735)
Grant commitments carried forward	<b>126,617</b>	87,576
Payable less than one year	<b>126,617</b>	87,576
Payable two to five years	-	-

## 7. Net expenditure for the period

This is stated after charging:	<b>Year ended 30 September 2022</b>	Year ended 30 September 2021
	<b>Total</b>	Total
	<b>£</b>	£
Depreciation	<b>1,944</b>	1,486
Examiners' remuneration:		
Examination	<b>5,415</b>	5,300
Payments made during period/year	-	-
Trustees' remuneration	-	-
Trustees' expenses	_____	_____

## 8. Staff costs and numbers

Staff costs were as follows:	<b>Year ended 30 September 2022</b>	Year ended 30 September 2021
	<b>Total</b>	Total
	<b>£</b>	£
Salaries and wages	<b>205,290</b>	182,602
Social security costs	<b>16,414</b>	13,020
Pension contributions	<b>1,616</b>	1,364
	_____	_____
	<b>223,320</b>	196,986
Consultant costs	<b>35,675</b>	66,655
	_____	_____
	<b>258,995</b>	263,641

During the year ended 30 September 2022 1 employee earned more than £60,000 (Year to 30 September 2021: 1). The pension contribution paid in respect of this employee totalled £Nil (2021: £Nil)

The key management personnel of the charity comprise the trustees and the chief executive.

The charity trustees do not receive remuneration. The total remuneration of the chief executive was £78,802 (year ended 30 September 2021: £66,494).

The average number of employees during the year was 7.5 (2021: 6.7)

The average number of employees during the year on a headcount basis was as follows:

	<b>2022</b>	2021
	<b>No.</b>	No.
Fundraising	<b>1.7</b>	2.1
Education and Awareness	<b>5.5</b>	4.3
Grant support	<b>0.3</b>	0.3
	_____	_____
Overall average	<b>7.5</b>	6.7

## 9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

## 10. Tangible fixed assets

Staff costs were as follows:	Computer and office equipment	Year ended 30 September 2022 Total £	Year ended 30 September 2021 Total £
<b>Cost</b>			
At the start of the period	7,315	<b>7,315</b>	3,224
Additions	2,864	<b>2,864</b>	4,091
At the end of the period	10,179	<b>10,179</b>	7,315
<b>Depreciation</b>			
At the start of the period	4,344	<b>4,344</b>	2,971
Charge for Period	1,944	<b>1,944</b>	1,486
At the end of the period	6,288	<b>6,288</b>	4,344
<b>Net book value</b>			
<b>At the end of the period</b>	3,891	<b>3,891</b>	2,971
At the start of the period	2,971	<b>2,971</b>	366

## 11. Intangible fixed assets

Staff costs were as follows:	Website development	Year ended 30 September 2022 Total £	Year ended 30 September 2021 Total £
<b>Cost</b>			
At the start of the period	-	-	-
Additions	9,204	<b>9,204</b>	-
At the end of the period	9,204	<b>9,204</b>	-
<b>Depreciation</b>			
At the start of the period	-	-	-
Charge for Period	-	-	-
At the end of the period	-	-	-
<b>Net book value</b>			
<b>At the end of the period</b>	9,204	<b>9,204</b>	-
At the start of the period	-	-	-



## 12. Debtors

	Year ended 30 September 2022	Year ended 30 September 2021
	Total £	Total £
Prepayments	10,071	45,594
Other debtors and accrued income	98,735	31,731
	<b>108,806</b>	<b>77,325</b>

## 13. Creditors: amounts due within one year

	Year ended 30 September 2022	Year ended 30 September 2021
	Total £	Total £
Grants Payable	126,617	87,576
Trade and Other Creditors	11,113	20,799
Accruals	32,779	40,495
	<b>170,509</b>	<b>148,870</b>

## 14. Movements in funds

	Brought forward £	Income £	Expenditure £	Carried forward £
<b>Unrestricted</b>				
General	157,158	441,214	(423,164)	175,208
Designated – Development	121,808	-	-	121,808
<b>Total unrestricted</b>	<b>278,966</b>	<b>441,214</b>	<b>(423,164)</b>	<b>297,016</b>
<b>Restricted</b>				
The National Lottery Community Fund - RC England-wide	32,445	166,673	(158,322)	40,796
Male Cancer Nurse Information Specialist - other funders	8,252	12,100	(16,752)	3,600
The Innovation Research Project	92,800	68,700	(7,320)	154,180
Penile Cancer Peer Support	-	8,500	(7,500)	1,000
Education and Awareness	5,000	58,950	(30,295)	33,655
Student Study and Travel Scholarships	6,729	-	(2,000)	4,729
Roadshows	2,860	42,871	(38,871)	6,860
Robert Lane Tissue Bank	-	42,800	(42,800)	-
Young Person's Testicular Cancer Project	3,228	-	(3,228)	-
City of London Corporation	10,000	-	(10,000)	-
<b>Total restricted</b>	<b>161,314</b>	<b>400,594</b>	<b>(317,088)</b>	<b>244,820</b>
<b>Total funds</b>	<b>440,280</b>	<b>841,808</b>	<b>(740,252)</b>	<b>541,836</b>

## 14. Movements in funds (continued)

Prior year	Brought forward	Income	Expenditure	Carried forward
	£	£	£	£
<b>Unrestricted</b>				
General	135,382	250,731	(228,955)	157,158
Designated – Research	53,281	-	(53,281)	-
Designated – Development	121,808	-	-	121,808
Designated – Awareness	83,658	-	(83,658)	-
<b>Total unrestricted</b>	<b>394,129</b>	<b>250,731</b>	<b>(365,894)</b>	<b>278,966</b>
<b>Restricted</b>				
Testicular Cancer Counselling	-	3,000	(3,000)	-
The National Lottery Community Fund - RC England-wide	-	89,497	(57,052)	32,445
Male Cancer Nurse Information Specialist - other funders	56,974	6,000	(54,722)	8,252
The Innovation Research Project	16,200	92,800	(16,200)	92,800
Penile Cancer Peer Support	5,000	2,500	(7,500)	-
Education and Awareness	11,250	23,050	(29,300)	5,000
Student Study and Travel Scholarships	6,729	-	-	6,729
Roadshows	37,527	1,000	(35,667)	2,860
Robert Lane Tissue Bank	-	57,700	(57,700)	-
Young Person's Testicular Cancer Project	10,369	-	(7,141)	3,228
National Lottery Community Fund – Covid 19 Emergency	37,328	-	(37,328)	-
City of London Corporation	7,500	4,000	(1,500)	10,000
<b>Total restricted</b>	<b>188,877</b>	<b>279,547</b>	<b>(307,110)</b>	<b>161,314</b>
<b>Total funds</b>	<b>583,006</b>	<b>530,278</b>	<b>(673,004)</b>	<b>440,280</b>

General funds are unrestricted funds available for use at the Trustees' discretion in furtherance of the general activities of the charity and which have not been designated for other purpose.

Designated Research funds represent monies set aside at the Trustees' discretion to be used to help fund the costs of future research programmes.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

## 15. Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total funds at 30 September 2022 £
Fixed Assets	13,095	-	13,095
Current Assets	454,430	244,820	699,250
Creditors due within one year	(170,509)	-	(170,509)
<b>Net assets at 30 September 2022</b>	<b>297,016</b>	<b>244,820</b>	<b>541,836</b>
Prior year analysis of net assets between funds			
Fixed Assets	2,971	-	2,971
Current Assets	424,865	161,314	586,179
Creditors due within one year	(148,870)	-	(148,870)
<b>Net assets at 30 September 2021</b>	<b>278,966</b>	<b>161,314</b>	<b>440,280</b>

## 16. Related party transactions

Restricted donations of £52,500 were received from Professor RTD Oliver, trustee, in the year ended 30 September 2022. (Year to 30 September 2021: £80,000).

## 17. Financial commitments

For the year ended 30 September 2022, the charity was committed to making the following future payments under non cancellable operating leases.

	Year ended 30 September 2022 Total £	Year ended 30 September 2021 Total £
<i>Land and buildings</i>		
Expiring within one year	14,184	14,184
Expiring within two to five years	-	-
	<b>14,184</b>	14,184

## 18. Capital commitments

At the year ended 30 September 2022, the charity had capital commitments of £9,204 (2021: £Nil).

